Theravance price target raised to $48 from $38 at RW Baird

theflyonthewall.com

Baird raised its price target on Theravance following Elan's bid for 21% of certain royalty rights. The firm believe it signals management's desire to monetize assets and gives an indication of what those assets are worth. Shares are Outperform rated.

Rates

View Comments (0)